IL292259A - flt3-targeted antibodies and their uses - Google Patents

flt3-targeted antibodies and their uses

Info

Publication number
IL292259A
IL292259A IL292259A IL29225922A IL292259A IL 292259 A IL292259 A IL 292259A IL 292259 A IL292259 A IL 292259A IL 29225922 A IL29225922 A IL 29225922A IL 292259 A IL292259 A IL 292259A
Authority
IL
Israel
Prior art keywords
antibodies targeting
targeting flt3
flt3
antibodies
targeting
Prior art date
Application number
IL292259A
Other languages
English (en)
Hebrew (he)
Inventor
Hemanta Baruah
Gregory P Chang
Ann F Cheung
Asya Grinberg
Zong Sean Juo
Thomas J Mcquade
Original Assignee
Dragonfly Therapeutics Inc
Hemanta Baruah
Gregory P Chang
Ann F Cheung
Asya Grinberg
Zong Sean Juo
Thomas J Mcquade
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Dragonfly Therapeutics Inc, Hemanta Baruah, Gregory P Chang, Ann F Cheung, Asya Grinberg, Zong Sean Juo, Thomas J Mcquade filed Critical Dragonfly Therapeutics Inc
Publication of IL292259A publication Critical patent/IL292259A/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2863—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against receptors for growth factors, growth regulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/70503—Immunoglobulin superfamily
    • C07K14/7051—T-cell receptor (TcR)-CD3 complex
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/31—Immunoglobulins specific features characterized by aspects of specificity or valency multispecific
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/33—Crossreactivity, e.g. for species or epitope, or lack of said crossreactivity
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/565—Complementarity determining region [CDR]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/60—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments
    • C07K2317/62—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments comprising only variable region components
    • C07K2317/622—Single chain antibody (scFv)
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/77—Internalization into the cell
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Immunology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Oncology (AREA)
  • Hematology (AREA)
  • Cell Biology (AREA)
  • Toxicology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Zoology (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
IL292259A 2019-10-15 2022-04-13 flt3-targeted antibodies and their uses IL292259A (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201962915120P 2019-10-15 2019-10-15
PCT/US2020/055480 WO2021076554A1 (en) 2019-10-15 2020-10-14 Antibodies targeting flt3 and use thereof

Publications (1)

Publication Number Publication Date
IL292259A true IL292259A (en) 2022-06-01

Family

ID=75538063

Family Applications (1)

Application Number Title Priority Date Filing Date
IL292259A IL292259A (en) 2019-10-15 2022-04-13 flt3-targeted antibodies and their uses

Country Status (16)

Country Link
US (1) US20240228628A9 (https=)
EP (1) EP4045537A4 (https=)
JP (1) JP2022551757A (https=)
KR (1) KR20220082882A (https=)
CN (1) CN115348972A (https=)
AR (1) AR120222A1 (https=)
AU (1) AU2020366000A1 (https=)
BR (1) BR112022006817A2 (https=)
CA (1) CA3153801A1 (https=)
CL (1) CL2022000927A1 (https=)
CO (1) CO2022004743A2 (https=)
IL (1) IL292259A (https=)
MX (1) MX2022004291A (https=)
PE (1) PE20221256A1 (https=)
TW (1) TWI867066B (https=)
WO (1) WO2021076554A1 (https=)

Families Citing this family (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EA202091887A1 (ru) 2018-02-08 2020-10-23 Драгонфлай Терапьютикс, Инк. Комбинированная терапия рака с применением мультиспецифических связывающих белков, которые активируют естественные клетки-киллеры
DK3749346T3 (da) 2018-02-08 2024-09-09 Dragonfly Therapeutics Inc Antistof variable domænekombinationer rettet mod nkg2d-receptoren
WO2020033630A1 (en) 2018-08-08 2020-02-13 Dragonfly Therapeutics, Inc. Multi-specific binding proteins that bind bcma, nkg2d and cd16, and methods of use
EA202091888A1 (ru) 2018-08-08 2020-10-23 Драгонфлай Терапьютикс, Инк. Вариабельные домены антител, нацеленные на рецептор nkg2d
US12378318B2 (en) 2018-08-08 2025-08-05 Dragonfly Therapeutics, Inc. Proteins binding NKG2D, CD16 and a tumor-associated antigen
EP4291233A4 (en) * 2021-02-10 2025-05-21 Wugen, Inc. POLYPEPTIDES AND THEIR USE IN THE TREATMENT OF DISEASES
JP2024508894A (ja) 2021-03-03 2024-02-28 ドラゴンフライ セラピューティクス， インコーポレイテッド Ｎｋｇ２ｄ、ｃｄ１６、及び腫瘍関連抗原に結合する多特異性結合タンパク質を使用して癌を治療する方法
US12162940B2 (en) 2021-05-05 2024-12-10 Immatics Biotechnologies Gmbh BMA031 antigen binding polypeptides
WO2023023491A1 (en) * 2021-08-16 2023-02-23 Hemogenyx Pharmaceuticals Llc Anti-flt3 antibodies, cars, car t cells and methods of use
WO2023105087A1 (en) * 2021-12-10 2023-06-15 Tubulis Gmbh Novel flt3 antibodies and antibody-drug-conjugates based thereon, therapeutic methods and uses thereof in combination with tyrosine kinase inhibitors

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AR071891A1 (es) * 2008-05-30 2010-07-21 Imclone Llc Anticuerpos humanos anti-flt3 (receptor tirosina cinasa 3 tipo fms humano)
NL2014108B1 (en) * 2015-01-09 2016-09-30 Aduro Biotech Holdings Europe B V Altered april binding antibodies.
ES2884844T3 (es) * 2015-03-09 2021-12-13 Agensys Inc Conjugados de anticuerpo fármaco (ADC) que se unen a proteínas FLT3
HK1255234A1 (zh) * 2015-07-16 2019-08-09 塞勒兰特治疗公司 经半胱氨酸取代的免疫球蛋白
CN118772278A (zh) * 2017-06-02 2024-10-15 辉瑞公司 Flt3的特异性抗体及其用途
JP7317718B2 (ja) * 2017-06-02 2023-07-31 ファイザー・インク Ｆｌｔ３を標的にするキメラ抗原受容体
WO2019023097A1 (en) * 2017-07-26 2019-01-31 Smet Pharmaceutical Inc ASYMMETRIC BISPECIFIC ANTIBODIES AND THEIR USE
TW201930344A (zh) * 2018-01-12 2019-08-01 美商安進公司 抗ｐｄ-１抗體及治療方法

Also Published As

Publication number Publication date
EP4045537A1 (en) 2022-08-24
CN115348972A (zh) 2022-11-15
WO2021076554A1 (en) 2021-04-22
TW202124449A (zh) 2021-07-01
CA3153801A1 (en) 2021-04-22
BR112022006817A2 (pt) 2022-07-05
TWI867066B (zh) 2024-12-21
AU2020366000A1 (en) 2022-05-12
CO2022004743A2 (es) 2022-07-08
MX2022004291A (es) 2022-05-10
PE20221256A1 (es) 2022-08-16
EP4045537A4 (en) 2024-07-17
US20240132598A1 (en) 2024-04-25
AR120222A1 (es) 2022-02-02
CL2022000927A1 (es) 2022-10-28
KR20220082882A (ko) 2022-06-17
US20240228628A9 (en) 2024-07-11
WO2021076554A8 (en) 2022-04-21
JP2022551757A (ja) 2022-12-13

Similar Documents

Publication Publication Date Title
IL292259A (en) flt3-targeted antibodies and their uses
ZA202006066B (en) Anti-hla-g antibodies and use thereof
IL282968A (en) Anti-NKG2A antibodies and their use
IL276950A (en) Anti-CD73 antibodies and uses thereof
ZA202006904B (en) Anti-il-4r antibody and use thereof
IL275737A (en) Variant antibodies against TIGIT
SG11202105885WA (en) Anti-claudin antibodies and uses thereof
SG11202100746WA (en) Anti-tigit antibody and use thereof
IL290141A (en) Formulations of anti-pvrig antibodies and uses thereof
IL275826A (en) Anti-mct1 antibodies and their uses
IL289585A (en) DLL3-targeted antibodies and uses thereof
IL278466B1 (en) Anti-dll3 antibodies and uses thereof
IL280321A (en) Antibodies against CXCR2 and their uses
IL291027A (en) Anti-steap1 antibodies and uses thereof
IL282707A (en) Anti-tim-3 antibodies and their use
IL281202A (en) Anti-TNFRSF9 antibodies and uses thereof
ZA202100714B (en) Anti-npr1 antibodies and uses thereof
IL282708A (en) Anti-tim-3 antibodies and their use
IL277075A (en) Anti-PHF-tau antibodies and uses thereof
SG11202009625WA (en) Anti-trem-1 antibodies and uses thereof
SG11202105161YA (en) Anti-il-27 antibodies and uses thereof
IL277330A (en) Anti-IL-27 antibodies and uses thereof
IL276548A (en) Binding antibodies - BCMA and their uses
SG11202012680TA (en) Anti-l1cam antibodies and uses thereof
IL277007A (en) Therapeutic ANTI-SPLA2-GIB antibodies and their uses